Novartis Ag (NVSEF) — SEC Filings

Overview

Novartis Ag (NVSEF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 20, 2025: Novartis AG announced on November 20, 2025, that it projects a 5-6% compound annual growth rate (CAGR) in constant currency (cc) sales from 2025 to 2030. This mid-term guidance was rolled forward following an upgrade of its 2024-2029 guidance to 6% cc. The company also upgraded peak sales guidance f

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 13 bullish, 20 neutral. The dominant filing sentiment for Novartis Ag is neutral.

Filing Type Overview

Novartis Ag (NVSEF) has filed 23 6-K, 2 20-F, 6 SC 13D/A, 1 SC 13D, 1 SC 13G/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (33)

• 6-K Filing — 6-K · Nov 25, 2025
• Novartis Projects 5-6% Sales CAGR 2025-2030 — 6-K · Nov 20, 2025 Risk: low
  Novartis AG announced on November 20, 2025, that it projects a 5-6% compound annual growth rate (CAGR) in constant currency (cc) sales from 2025 to 2030. This m
• Novartis Issues Over $5 Billion in Notes — 6-K · Nov 5, 2025 Risk: low
  Novartis AG, through its subsidiary Novartis Capital Corporation, announced the issuance of several tranches of notes on November 5, 2025. These include $800 mi
• Novartis AG Files Q3 2025 Financial Report on Form 6-K — 6-K · Oct 28, 2025 Risk: low
  Novartis AG filed a Form 6-K on October 28, 2025, reporting on its financial performance for the period ending September 30, 2025. The filing includes Exhibits
• Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences — 6-K · Oct 27, 2025 Risk: medium
  Novartis AG announced on October 27, 2025, an agreement to acquire Avidity Biosciences, a company focused on RNA therapeutics. This acquisition aims to bolster
• FDA Approves Novartis' Rhapsido for Chronic Spontaneous Urticaria — 6-K · Sep 30, 2025 Risk: low
  Novartis AG announced on September 30, 2025, that the FDA has approved Rhapsido® (remibrutinib). This is the only oral, targeted BTKi treatment for chronic spon
• Novartis ianalumab trials meet Sjögren's disease endpoints — 6-K · Aug 11, 2025 Risk: low
  Novartis AG announced on August 11, 2025, that its Phase III clinical trials, NEPTUNUS-1 and NEPTUNUS-2, for ianalumab in patients with Sjögren's disease, met t
• Novartis AG Files Q2 2025 Financial Report — 6-K · Jul 17, 2025 Risk: low
  Novartis AG filed a Form 6-K on July 17, 2025, reporting its financial results for the period ending June 30, 2025. The filing includes Exhibit 99.1, the Financ
• Novartis Appoints Mukul Mehta as New CFO, Harry Kirsch Retires — 6-K · Jul 17, 2025 Risk: low
  Novartis AG announced on July 17, 2025, that Mukul Mehta will become the new Chief Financial Officer (CFO) effective March 16, 2026. Mehta, currently Head of Bu
• Novartis Pluvicto Shows Strong Prostate Cancer Benefit — 6-K · Jun 2, 2025 Risk: low
  Novartis AG announced on June 2, 2025, that its drug Pluvicto™ demonstrated a statistically significant and clinically meaningful improvement in radioligand pro
• Novartis AG Files Q1 2025 Financial Report — 6-K · Apr 29, 2025 Risk: low
  Novartis AG filed a Form 6-K on April 29, 2025, reporting its Q1 2025 financial results. The filing includes Exhibit 99.1, a Financial Report for Q1 2025, and E
• Novartis Vanrafia® Gets FDA Accelerated Approval for IgAN — 6-K · Apr 3, 2025 Risk: low
  Novartis AG announced on April 3, 2025, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan). This drug
• FDA OKs Earlier Pluvicto Use for Prostate Cancer — 6-K · Mar 28, 2025 Risk: low
  On March 28, 2025, Novartis AG announced that the U.S. Food and Drug Administration (FDA) has approved an earlier use of its radioligand therapy, Pluvicto®, for
• Novartis AG Files 2024 Annual Report — 20-F · Jan 31, 2025 Risk: medium
  Novartis AG filed its 20-F for the fiscal year ending December 31, 2024. The filing provides financial statements and disclosures for the company, which operate
• Novartis SMA Drug Hits Phase III Endpoint — 6-K · Dec 30, 2024 Risk: low
  Novartis AG announced on December 30, 2024, that its Phase III study for intrathecal onasemnogene abeparvovec met its primary endpoint in children and young adu
• Novartis Upgrades Guidance, Highlights Pipeline — 6-K · Nov 25, 2024 Risk: low
  Novartis AG announced on November 21, 2024, that it is upgrading its mid-term guidance and emphasizing its pipeline to drive long-term growth. The company highl
• Novartis AG Files Q3 2024 Financial Report — 6-K · Oct 29, 2024 Risk: low
  Novartis AG filed a Form 6-K on October 29, 2024, reporting its Q3 2024 financial results. The filing includes a Financial Report for Q3 2024 and an Interim Fin
• Novartis Scemblix FDA Approved for Newly Diagnosed CML — 6-K · Oct 29, 2024 Risk: low
  Novartis AG announced on October 29, 2024, that the U.S. Food and Drug Administration (FDA) has approved Scemblix® (asciminib) for the treatment of newly diagno
• Novartis AG Files SC 13D/A Amendment for MorphoSys AG — SC 13D/A · Oct 17, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco Germany AG, has filed an amendment (Amendment No. 6) to its Schedule 13D regarding MorphoSys AG. The filing,
• Novartis Issues Over $3.7 Billion in New Notes — 6-K · Sep 18, 2024 Risk: low
  Novartis AG, through its subsidiary Novartis Capital Corporation, announced the issuance of new notes on September 18, 2024. The issuance includes $1,000,000,00
• FDA Approves Novartis Kisqali for Early Breast Cancer — 6-K · Sep 17, 2024 Risk: low
  On September 17, 2024, Novartis AG announced that the U.S. Food and Drug Administration (FDA) approved Kisqali® (ribociclib) to reduce the risk of recurrence in
• Novartis AG Files SC 13D/A Amendment for MorphoSys AG — SC 13D/A · Aug 15, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco Germany AG, has filed an amendment (Amendment No. 5) to its Schedule 13D concerning MorphoSys AG. The filing,
• Novartis Fabhalta FDA Accelerated Approval for IgAN — 6-K · Aug 8, 2024 Risk: low
  Novartis AG announced on August 7, 2024, that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Fabhalta® (iptacopan). This drug is t
• Novartis AG Files Q2 2024 Financial Report — 6-K · Jul 18, 2024 Risk: low
  Novartis AG filed a Form 6-K on July 18, 2024, reporting its financial information as of June 30, 2024. The filing includes Exhibit 99.1, a Financial Report for
• Novartis AG Amends MorphoSys AG Filing — SC 13D/A · Jun 21, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco Germany AG, has amended its Schedule 13D filing concerning MorphoSys AG. The amendment, filed on June 21, 202
• Novartis AG Amends Schedule 13D for MorphoSys AG — SC 13D/A · Jun 17, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco AG, has filed an amendment (no. 3) to its Schedule 13D concerning MorphoSys AG. This filing, dated June 17, 2
• Novartis Amends MorphoSys Acquisition Filing — SC 13D/A · Jun 10, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco AG, filed an amendment (No. 2) to its Schedule 13D on June 10, 2024, regarding its acquisition of MorphoSys A
• Novartis AG Amends MorphoSys AG Filing — SC 13D/A · May 28, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco AG, has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of MorphoSys
• Novartis AG Files Q1 2024 Financial Reports — 6-K · Apr 23, 2024 Risk: low
  Novartis AG filed a Form 6-K on April 23, 2024, reporting on its Q1 2024 financial results. The filing includes a Financial Report for Q1 2024 and an Interim Fi
• Novartis Launches Tender Offer for MorphoSys AG — SC 13D · Apr 18, 2024 Risk: medium
  Novartis AG, through its subsidiary Novartis Bidco AG, has filed a Schedule 13D, indicating a tender offer for MorphoSys AG ordinary shares. The filing, dated A
• BlackRock Amends Novartis Stake, Maintains Passive Position — SC 13G/A · Feb 2, 2024
  BlackRock Inc. filed an amended SC 13G/A on February 2, 2024, disclosing its ownership in Novartis AG (NYSE: NVS) as of December 31, 2023. This amendment, numbe
• Novartis AG Files 20-F Report for Fiscal Year Ended December 31, 2023 — 20-F · Jan 31, 2024 Risk: low
  NOVARTIS AG (NVSEF) filed a Foreign Annual Report (20-F) with the SEC on January 31, 2024. Novartis AG filed its annual report on Form 20-F for the fiscal year
• Novartis Scemblix® Beats Standard TKIs in CML Phase III Trial — 6-K · Jan 8, 2024
  Novartis AG announced on January 8, 2024, that its drug Scemblix® (asciminib) achieved superior major molecular response (MMR) rates compared to standard-of-car

Risk Profile

Risk Assessment: Of NVSEF's 30 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Paul Penepent
• Mukul Mehta
• Harry Kirsch
• Karen L. Hale

Industry Context

Novartis AG operates in the pharmaceutical preparations industry, a sector focused on the research, development, manufacturing, and marketing of drugs and medicines.

Top Tags

pharmaceuticals (13) · amendment (7) · financial-report (6) · quarterly-results (5) · drug-launch (5) · acquisition (3) · fda-approval (3) · drug-development (3) · sec-filing (3) · FDA-approval (3)

Key Numbers

• cc sales CAGR: +5-6% — Projected compound annual growth rate for sales from 2025-2030
• de-risked assets: 8 — Number of in-market assets with significant peak sales potential
• Total Notes Issued: $5.15B — Sum of all announced note issuances ($800M + $700M + $1.75B + $925M + $925M)
• Maturity Year: 2028 — Multiple note tranches mature in 2028
• Fiscal Year: 2024 — The primary year for which financial information is reported in this 20-F.
• Prior Fiscal Year: 2023 — Comparative financial data for the previous year is included.
• Total Debt Issued: $3.7B — Aggregate principal amount of all notes issued ($1B + $0.85B + $1.1B + $0.75B).
• 2029 Notes Interest Rate: 3.800% — Coupon rate for the notes due in 2029.
• 2054 Notes Interest Rate: 4.700% — Coupon rate for the notes due in 2054.
• Fiscal Year End: 2023 — Conformed Period of Report
• Filed As Of Date: 2024-01-31 — Filed As Of Date
• Public Document Count: 270 — Public Document Count
• Report End Date: 2023-12-31 — Conformed Period of Report

Related Companies

NVTS · NVS · MOR

Frequently Asked Questions